Table 1 Baseline characteristics and variables at enrollment
Variable | All (N = 65) | Responder (N = 30) | Non-responder (N = 35) | P value |
|---|---|---|---|---|
Clinical feature | ||||
Age, year | 64.51 ± 8.33 | 65.47 ± 8.86 | 63.69 ± 7.89 | 0.395 |
Male sex, n (%) | 52 (80.0%) | 21 (70.0%) | 31 (88.6%) | 0.062 |
Body height (cm) | 161.95 ± 9.97 | 162.4 ± 7.8 | 161.7 ± 11.6 | 0.781 |
Body weight (kg) | 69.68 ± 10.93 | 70.02 ± 11.96 | 69.38 ± 10.13 | 0.814 |
Body mass index (kg/m2) | 26.65 ± 4.36 | 26.50 ± 3.71 | 26.77 ± 4.89 | 0.990 |
Former smoker, n (%) | 26 (40.0%) | 16 (53.3%) | 10 (28.6%) | 0.042 |
Hypertension, n (%) | 59 (90.8%) | 26 (86.7%) | 33 (94.3%) | 0.403 |
Diabetes mellitus, n (%) | 50 (76.9%) | 23 (76.7%) | 27 (77.1%) | 0.964 |
Dyslipidemia, n (%) | 57 (87.7%) | 25 (83.3%) | 32 (91.4%) | 0.455 |
Old stroke, n (%) | 26 (23.1%) | 8 (26.7%) | 7 (20.0%) | 0.525 |
Old myocardial infarction, n (%) | 16 (24.6%) | 5 (16.7%) | 11 (31.4%) | 0.168 |
Chronic hepatitis B or C, n (%) | 5 (7.7%) | 1 (3.3%) | 4 (11.4%) | 0.363 |
History of CABG, n (%) | 22 (33.8%) | 7 (23.3%) | 15 (49.2%) | 0.097 |
History of PCI, n (%) | 45 (69.2%) | 21 (70.0%) | 24 (68.6%) | 0.901 |
Left main involvement, n (%) | 19 (29.2%) | 7 (23.3%) | 12 (34.3%) | 0.333 |
Multi-vessel CAD, n (%) | 68 (100%) | 40 (100%) | 28 (100%) | 1.000 |
CTO at LAD, n (%) | 35 (53.8%) | 16 (53.3%) | 19 (54.3%) | 0.939 |
Laboratory data | ||||
Leukocyte count, 1000/μL | 7.00 ± 2.00 | 6.50 ± 2.07 | 7.44 ± 1.86 | 0.017 |
Hemoglobin, g/dL | 13.24 ± 1.87 | 13.14 ± 2.04 | 13.32 ± 1.73 | 0.707 |
Platelet count, 1000/μL | 201.88 ± 57.11 | 193.1 ± 44.3 | 209.4 ± 65.9 | 0.254 |
Serum creatinine, mg/dL | 1.28 ± 0.52 | 1.25 ± 0.56 | 1.31 ± 0.48 | 0.116 |
eGFR, ml/min/1.73 m2 | 61.33 ± 21.53 | 62.19 ± 22.73 | 60.60 ± 20.74 | 0.770 |
Serum sodium, mEq/L | 140.11 ± 2.69 | 140.30 ± 2.89 | 139.94 ± 2.54 | 0.531 |
Serum potassium, mEq/L | 4.28 ± 0.42 | 4.35 ± 0.40 | 4.22 ± 0.44 | 0.231 |
Alanine aminotransferase, U/L | 27.02 ± 23.33 | 27.67 ± 28.88 | 26.46 ± 17.68 | 0.594 |
Total cholesterol, mg/dL | 163.49 ± 42.01 | 167.03 ± 36.86 | 160.46 ± 26.30 | 0.378 |
Low-density lipoprotein, mg/dL | 96.23 ± 36.34 | 99.03 ± 34.73 | 93.83 ± 38.00 | 0.569 |
High-density lipoprotein, mg/dL | 43.74 ± 9.79 | 43.97 ± 11.29 | 43.54 ± 8.45 | 0.863 |
Triglyceride, mg/dL | 143.20 ± 79.20 | 132.13 ± 49.16 | 152.69 ± 97.71 | 0.989 |
Medication | ||||
Antiplatelet, n (%) | 65 (100.0%) | 30 (100.0%) | 35 (100.0%) | 1.000 |
Anticoagulant, n (%) | 2 (3.1%) | 0 (0.0%) | 2 (5.7%) | 0.495 |
Beta-blocker, n (%) | 58 (89.2%) | 20 (100.0%) | 28 (80.0%) | 0.013 |
RAS inhibitor, n (%) | 54 (83.1%) | 23 (76.7%) | 31 (88.6%) | 0.202 |
Calcium channel blocker, n (%) | 31 (47.7%) | 12 (40.0%) | 19 (54.3%) | 0.250 |
Diuretic, n (%) | 22 (33.8%) | 6 (20.0%) | 16 (45.7%) | 0.029 |
Lipid lowering agent, n (%) | 45 (69.2%) | 20 (66.7%) | 25 (71.4%) | 0.678 |
Vasodilator, n (%) | 2 (3.1%) | 0 (0.0%) | 2 (5.7%) | 0.495 |